Patents
Literature
Patsnap Copilot is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Patsnap Copilot

58 results about "Cosmeceutical" patented technology

Cosmeceuticals are cosmetic products with bioactive ingredients purported to have medical benefits. There are no legal requirements to prove that these products live up to their claims. The name is a combination of "cosmetics" and "pharmaceuticals". "Nutricosmetics" are related dietary supplement or food or beverage products with additives that are marketed as having medical benefits that affect appearance.

Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like

Systems and methods for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and treating hyperglycemia, Alzheimer's disease, sleep disorders, Parkinson's disease, Attention Deficit Disorder and nicotine addiction involve synchronizing and tailoring the administration of nutraceuticals, medications and other substances (for example, stimulants) in accordance with the body's natural circadian rhythms, meal times and other factors. Improved control of blood glucose levels, extended alertness, and weight control, and counteracting of disease symptoms when they are at their worst are possible. An automated, pre-programmable transdermal administration system is used to provide pulsed doses of medications, pharmaceuticals, hormones, neuropeptides, anorexigens, pro-drugs, stimulants, plant extracts, botanicals, nutraceuticals, cosmeceuticals, phytochemicals, phytonutrients, enzymes, antioxidants, essential oils, fatty acids, minerals, vitamins, amino acids, coenzymes, or other physiological active ingredient or precursor. The system can utilize a pump, pressurized reservoir, a system for removing depleted carrier solution, or other modulated dispensing actuator, in conjunction with porous membranes or micro-fabricated structures.
Owner:MORNINGSIDE VENTURE INVESTMENTS

Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like

Systems and methods for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and treating hyperglycemia, Alzheimer's disease, sleep disorders, Parkinson's disease, Attention Deficit Disorder and nicotine addiction involve synchronizing and tailoring the administration of nutraceuticals, medications and other substances (for example, stimulants) in accordance with the body's natural circadian rhythms, meal times and other factors. Improved control of blood glucose levels, extended alertness, and weight control, and counteracting of disease symptoms when they are at their worst are possible. An automated, pre-programmable transdermal administration system is used to provide pulsed doses of medications, pharmaceuticals, hormones, neuropeptides, anorexigens, pro-drugs, stimulants, plant extracts, botanicals, nutraceuticals, cosmeceuticals, phytochemicals, phytonutrients, enzymes, antioxidants, essential oils, fatty acids, minerals, vitamins, amino acids, coenzymes, or other physiological active ingredient or precursor. The system can utilize a pump, pressurized reservoir, a system for removing depleted carrier solution, or other modulated dispensing actuator, in conjunction with porous membranes or micro-fabricated structures.
Owner:MORNINGSIDE VENTURE INVESTMENTS

Dry emollient compositions

The present invention are dry-feel emollient compositions comprising jojoba oil based esters that have use in personal care, cosmetic, cosmaceutical and pharmaceutical products. These compositions are essentially solid at room temperature, can be provided in various shapes and sizes (especially as particulates such as spheres), and can be produced from combinations of fatty alcohols, isopropyl esters and wax esters obtained from the oil contained in the seed of the jojoba plant. These new compositions also increase the range of applications for cosmetic compositions through an emollient that is more polar and hydrophilic than is found in jojoba oils. The compositions of the present invention may be obtained by a novel process of a base catalyzed alcoholysis reaction between jojoba oil and an alcohol, such as isopropyl alcohol. These components, whether exclusively jojoba esters or when combined with other carrier and vehicle components (including other emollients or binders) can form excellent carrier composition for use in the cosmetic, personal care and/or pharmaceutical field. Typical materials with which the compositions of the present invention may be blended include, but are not limited to, cosmetic oils and waxes, both natural and synthetic, (including hydrogenated or partially hydrogenated oils), silicone oils, mineral oils, long chain esters, vitamins, long chain fatty acids, cosmeceuticals, pigments, botanical extracts, esters and ethers, dimers, trimers, oligomers, and polymers, and the like. The proportions of the jojoba esters should be chosen to provide the dry-feel to the composition, which is highly desired. This will usually require a weight percent that ranges from 10% to 100% by weight of carrier material in the composition.
Owner:INT FLORA TECH

Traditional Chinese medicine itching-relieving gel and preparation method thereof

The invention belongs to the technical field of medicines and relates to traditional Chinese medicine itching-relieving gel. The traditional Chinese medicine itching-relieving gel is prepared from raw materials comprising Chinese violet, cortex dictamni and sophora flavescens at a mass ratio of 2:1:1. The invention further relates to a preparation method of the traditional Chinese medicine itching-relieving gel. The preparation method comprises the following steps: (1) performing preparation of concentrated solution decocted with water of a traditional Chinese medicine; (2) performing preparation of gel substrate; and (3) finally adding the concentrated solution decocted with the water of the itching-relieving traditional Chinese medicine to the gel substrate, uniformly stirring, and cooling down at low temperature. According to the preparation method provided by the invention, the auxiliary of the gel comprises the following components in parts by weight: 12-14 parts of hydroxyethyl cellulose, 5-8 parts of avicel CL-611, 100 parts of glycerol, 50 parts of absolute ethyl alcohol, 15 parts of azone, 300-400 parts of distilled water, 0-3 parts of carrageen and 0-1 part of sodium hydroxide. The traditional Chinese medicine itching-relieving gel disclosed by the invention is applied to medicines for treating skin itch caused by various reasons, such as eczema, urticaria and pruritus; and in addition, cosmeceuticals can be prepared by adding 5-10 parts of lavender essential oil or menthol essential oil to the traditional Chinese medicine itching-relieving gel.
Owner:上海国创医药股份有限公司

Recombinant human fibronectin III1-C, and preparation method and application thereof

The invention discloses a recombinant human fibronectin III1-C (rhFNIII1-C), and a preparation method and application thereof. The preparation method comprises the following steps: optimizing a targetgene segment of the target protein according to codon expression preference, and inserting the obtained gene segment into pET-32a to construct a recombinant plasmid; transforming and introducing therecombinant plasmid into an expression vector BL21(DE3), and carrying out screening to obtain positive clone bacteria capable of realizing efficient soluble expression; carrying out enlarging fermentation culture on the positive clone bacteria, carrying out induced expression, performing crushing and centrifuging to obtain a supernatant, and carrying out purification through elution with a His-tagaffinity chromatography column, dialysis, filtration and other steps to obtain a high-quality rhFNIII 1-C solution with a protein concentration of 1.0 mg/mL or above and a purity of 90% or above. According to detection and observation results of cell adhesion promoting tests, the rhFNIII1-C has the performance of obviously promoting adherence and adhesion of MDBK cells and Balb/c/3T3 cells and rapid division and growth of the cells, which indicates that the rhFNIII1-C has huge potential of being used as a raw material and a finished product for cosmeceuticals and medical skincare.
Owner:ANHUI MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products